Skip to content
Bora Haber
Markets
  • US dollar50.44up 0.05%
  • Euro55.34down 0.18%
  • British pound66.55down 0.11%
  • BIST 10011,477down 3.08%
  • Gold (gram)6,041down 3.55%
  • Gold (ounce)US$3,725down 3.6%
  • BitcoinUS$62,686down 1.61%
BREAKING

FDA warns of vision loss risk with weight-loss and diabetes drugs

The US Food and Drug Administration has asked makers of Ozempic, Wegovy and Mounjaro to add to their labels the risk of NAION, a rare eye condition that can cause permanent vision loss.

Nehir Gökçe

· 2 min read

A doctor in a white coat examines a young girl's eye with an ophthalmoscope in a clinic room.
An eye examination in a clinic; regular vision checks are important for patients taking these medications. Temsili görsel · Fotoğraf: Pavel Danilyuk / Pexels

The US Food and Drug Administration (FDA) has issued a new safety warning for drugs used in diabetes and weight-loss treatment, such as Ozempic, Wegovy and Mounjaro. Under the requirement, manufacturers must add a warning to the drugs' safety labels about an eye disease that, although very rare, can cause permanent vision loss.

What is NAION?

The condition is called NAION. It occurs when the blood vessels that feed the optic nerve become blocked, and it can cause sudden, painless vision loss in one eye. There is no known treatment that can reverse the vision loss caused by the disease.

Studies hard to assess

The FDA said some studies on the issue were difficult to evaluate. The reason is that people who take these drugs for obesity and type 2 diabetes may have risk factors for NAION regardless of the medication. The agency said it is not yet known why the risk of the eye disease may be higher in people using these drugs.

Novo Nordisk, the maker of Wegovy, announced that it believes the current data do not establish a cause-and-effect relationship between the drug and the disease.

Background

The risk was first raised by a scientific study published in 2024. In that study, which examined a large group of patients, people using semaglutide were found to be four times more likely to be diagnosed with NAION than those not using it. One of the study's authors, ophthalmology professor Dr. Joseph Rizzo, said the findings were "important but not yet conclusive" and stressed that further research in different patient groups was needed.

In 2025, the European Medicines Agency also recognized NAION as a very rare side effect of semaglutide-containing drugs. A safety committee of the agency said last year that the rate of people affected among users was extremely low. The FDA's latest statement has revived earlier debates over the risk.

Science guides

Take a quiz, vote in a poll

Video news

Comments

Sign in to comment.

More on this topic

See all